Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
Sell
-12,333
Closed -$301K 319
2024
Q3
$301K Sell
12,333
-2,273
-16% -$60.8K 0.04% 240
2024
Q2
$367K Sell
14,606
-181
-1% -$5.13K 0.05% 201
2024
Q1
$442K Buy
14,787
+161
+1% +$4.73K 0.07% 184
2023
Q4
$466K Sell
14,626
-404
-3% -$12.7K 0.09% 165
2023
Q3
$530K Sell
15,030
-1,711
-10% -$65.2K 0.11% 124
2023
Q2
$636K Sell
16,741
-370
-2% -$14.8K 0.12% 112
2023
Q1
$646K Sell
17,111
-633
-4% -$24.3K 0.13% 121
2022
Q4
$752K Sell
17,744
-2,982
-14% -$123K 0.15% 106
2022
Q3
$666K Buy
20,726
+15
+0.1% +$527 0.15% 107
2022
Q2
$673K Buy
20,711
+3,982
+24% +$129K 0.14% 107
2022
Q1
$605K Sell
16,729
-1,792
-10% -$61.5K 0.1% 128
2021
Q4
$733K Sell
18,521
-920
-5% -$38.4K 0.12% 119
2021
Q3
$850K Sell
19,441
-525
-3% -$23.6K 0.15% 112
2021
Q2
$815K Sell
19,966
-6
-0% -$232 0.14% 104
2021
Q1
$656K Buy
19,972
+3,202
+19% +$120K 0.13% 120
2020
Q4
$682K Sell
16,770
-2,230
-12% -$83.4K 0.14% 94
2020
Q3
$696K Buy
19,000
+435
+2% +$15.7K 0.15% 85
2020
Q2
$629K Sell
18,565
-2,804
-13% -$76.4K 0.15% 87
2020
Q1
$453K Buy
21,369
+5,543
+35% +$124K 0.12% 94
2019
Q4
$353K Buy
15,826
+5,920
+60% +$129K 0.08% 131
2019
Q3
$201K Buy
+9,906
New +$195K 0.05% 164

Other funds holding GMAB

LVW Advisors's GMAB Position: Q4 2024 in Review

LVW Advisors sold out of Genmab (GMAB) in Q4 2024, closing a stake of 12,333 shares — an estimated $301K sold.

LVW Advisors first reported a position in GMAB in Q3 2019 and held it in 21 quarters. The position peaked at $850K in Q3 2021. 228 funds tracked by Wall St. Rank hold GMAB as of Q4 2024.

  • LVW Advisors reported no remaining Genmab position as of Q4 2024 after selling out during the quarter.
  • LVW Advisors sold 12,333 Genmab shares in Q4 2024, an estimated $301K.
  • LVW Advisors first reported a position in Genmab in Q3 2019 and held it in 21 quarters.
  • LVW Advisors's Genmab position peaked at $850K in Q3 2021.
  • 228 funds tracked by Wall St. Rank held Genmab as of Q4 2024.

Based on LVW Advisors's 13F filing for Q4 2024, filed 16 Jan 2025.